Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Return on Sales (2017 - 2025)

Lexaria Bioscience's Return on Sales history spans 9 years, with the latest figure at 20.62% for Q4 2025.

  • For Q4 2025, Return on Sales fell 599.0% year-over-year to 20.62%; the TTM value through Nov 2025 reached 20.62%, down 593.0%, while the annual FY2025 figure was 16.83%, 447.0% down from the prior year.
  • Return on Sales for Q4 2025 was 20.62% at Lexaria Bioscience, down from 15.44% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.14% in Q2 2022 and bottomed at 210.06% in Q4 2023.
  • The 5-year median for Return on Sales is 15.62% (2025), against an average of 31.06%.
  • The largest annual shift saw Return on Sales crashed -19272bps in 2023 before it soared 19543bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 144.34% in 2021, then surged by 88bps to 17.35% in 2022, then crashed by -1111bps to 210.06% in 2023, then skyrocketed by 93bps to 14.63% in 2024, then tumbled by -41bps to 20.62% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Return on Sales are 20.62% (Q4 2025), 15.44% (Q3 2025), and 21.55% (Q2 2025).